A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis
Status:
Recruiting
Trial end date:
2023-02-10
Target enrollment:
Participant gender:
Summary
This is a prospective study to investigate the treatment response of Tocilizumab on patients
with idiopathic retroperitoneal fibrosis（IRPF）.
Methods: All the patients fulfilling diagnostic criteria of IRPF would be enrolled. The IRPF
patients will accept Tocilizumab or Glucocorticoid monotherapy for 3 months.
Endpoints: The primary endpoint is to investigate the response of Tocilizumab on IRPF
patients; the secondary endpoints include the decrease of inflammatory markers, side effect.